High-throughput diagnostic system for tissue-based personalized cancer therapy

Volker Bruns Group Manager Medical Image Processing and Machine Learning

Fraunhofer-Institute for Integrated Circuits IIS volker.bruns@iis.fraunhofer.de

on Behalf of

Dr. Christian Münzenmayer

Head of Image Processing and Medical Engineering Department

Fraunhofer-Institute for Integrated Circuits IIS

Am Wolfsmantel 33, 91058 Erlangen

christian.muenzenmayer@iis.fraunhofer.de E-Mail:

Phone: +49-(0)9131-776-7300







Fraunhofer Who we are




Europe's leading applied research organization with 24,000 employees, 2.1B€ annual budget and more than 20,000 patents.

Fraunhofer is home to leading experts in AI, healthcare visualization, diagnostic research and computational medicine.






Where we stand today **Personalized Therapy – Hoping for improvement**







Where we stand today **Personalized Therapy – Hoping for improvements**



Check tumor and select therapy


Goal: We need to improve therapy for our patients by analysing the target cells. Possibly DCCs are more sensitive to drugs than metastases.
















Werner-Klein et al., Nature Communications 2018













Werner-Klein et al., Nature Communications 2018












Werner-Klein et al., Nature Communications 2018










Werner-Klein et al., Nature Communications 2018






















ITEM





Our approach - a paradigm shift in diagnostics From tissue sections.... to single cell analysis












Our approach - a paradigm shift in diagnostics Single cell analysis from lymph nodes


Histopathology on FFPE tissue



139/1027 patients positive (14%)

Ulmer et al., Plos Medicine 2014

Single cell analysis



525/1027 patients positive (51%)

gp100 staining (Melanocytic marker) for detecting DCCs

© Fraunhofer IIS

ITEM






Our approach - a paradigm shift in diagnostics Single cell analysis from lymph nodes

Fraunhofer


ITEM



Number of patients at risk (at the corresponding months)

Risk group	0	30	60	90
DCCD=0	502	402	165	55
0 <dccd≤3< td=""><td>249</td><td>205</td><td>98</td><td>27</td></dccd≤3<>	249	205	98	27





risk of death doubles with every 10x increase of the amount of DCCs.

💹 Fraunhofer 🛛 🗾 Fraunhofer


IPA

13

IIS

Ulmer et al., Plos Medicine 2014

Our approach - a paradigm shift in diagnostics Towards automating single cell analysis








ΙΡΑ



Our approach - a paradigm shift in diagnostics Towards automating single cell analysis








ΙΡΑ



TissueGrinder Enabling automated, enzyme-free tissue dissociation



© Fraunhofer IIS








TissueGrinder Function and Workflow

- 1. Tissue sample loading in Grinding Tube
- 2. Assembling of **Grinding Tube**







IPA

3. Efficient dissociation

by intelligent process

control




4. Subsequent

centrifugation in

closed sterile system

Our approach - a paradigm shift in diagnostics Towards automating single cell analysis








Automated Microscopy Scanning and analysis

- Automated scan process
- Tumor cell detection and visualization
- Export of tumor cell coordinates







19










Automated Microscopy Scan process






ΙΡΑ

llS

Automated Microscopy Automated Detection of DCCs in chopped lymph nodes






IPA



Automated Microscopy

Automated Detection of DCCs in chopped lymph nodes




ITEM



IPA

Automated Microscopy Classification of candidate objects




Fraunhofer

ITEM



IPA

Our approach - a paradigm shift in diagnostics Towards automating single cell analysis








ΙΡΑ



Molecular Assay Single cell analysis from lymph nodes



 \Rightarrow Molecular single cell analysis identifies somatic mutations and CNVs correlated with lymph node colonization and poor prognosis






IPA



Molecular Assay Deterministic single cell Whole Genome Amplification (WGA)










Molecular Assay Compare primary melanoma to single lymph node cells




🗾 Fraunhofer

ITEM


early DCCs are genetically immature and acquire critical alterations after \Rightarrow homing to a distant site and thereby gain the ability to form a colony

Werner-Klein et al., Nature Communications 2018





Molecular Assay Identification of a molecular colonization signature




- \Rightarrow Presence of at least one of these mutations increases risk of death
- ⇒ Molecular single cell analysis can identify patients with risk of systemic progression

Werner-Klein et al., Nature Communications 2018





Our approach - a paradigm shift in diagnostics Towards automating single cell analysis









ΙΡΑ





IIS

Workflow Management (Merlin) **Fact Sheet**



*) as long as they support modern web-based APIs and a sufficient set of capabilities







Summary and Conclusion From sections to single cell diagnostics

We work on a new paradigm for lymph node diagnostics

Benefits

- ✓ Higher sensitivity compared to conventional sections diagnostic
- ✓ Modular approach for highest flexibility
- ✓ Improved stratification
- ✓ Reduced cost

Tissue Grinder Automated Microscopy Molecular Assay



Workflow Management

Fraunhofer Innovations







